+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are investigating the safety, feasibility, and preliminary effectiveness of expanded allogeneic mesenchymal stem cells derived from adipose tissue HC106 for treating urinary incontinence in women over 50 years old. This phase I controlled trial aims to compare the effects of HC106 cells with a placebo in women diagnosed with stress or mixed urinary incontinence who have not responded to or declined rehabilitative or surgical treatments. Participants are divided into two groups one receives a single dose of 40 million HC016 cells injected near the external urinary sphincter, and the other receives a placebo consisting of the saline solution used to condition the cells. The injection procedure involves anesthesia, identifying the target area via cystoscopy, and carefully injecting the cell suspension at two specific points. The placebo group undergoes the same procedure using saline solution. The study uses a randomized, double-blind design. Throughout the study, participants are monitored for complications within 7 days after treatment and assessed for urinary leakage, flowmetry, and quality of life at 3 and 6 months using standardized tests and questionnaires. Researchers track safety, treatment effects, and quality of life changes over time. The total duration of participation includes initial treatment and follow-up visits up to six months.

Age: 50Years +FEMALEPhase 1
6 locations
C

Actively Recruiting

Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.

All AgesAll Genders
305 locations
M

Actively Recruiting

Researchers are evaluating the effect of 12 months of continuous positive airway pressure CPAP treatment combined with conventional pharmacological therapy on lipid profiles in patients with dyslipidemia and moderate to severe obstructive sleep apnea OSA. This phase IV randomized, open-label, parallel clinical trial aims to explore improvements in blood lipid levels, serum uric acid, insulin resistance, cardiovascular risk, glycemic control, inflammation markers, and quality of life in this patient group aged 35 to 80 years. Participants will be randomly assigned to one of two groups one receiving standard hygienic-dietary advice and promotion of daily physical activity, and the other receiving the same plus CPAP therapy. CPAP treatment starts with an empirical pressure of 8 cmH2O and is adjusted within three weeks via automatic titration to a pressure corresponding to the 95th percentile. Patients in both groups will be encouraged to walk 10,000 steps daily, monitored with pedometers and step logs. During the 12-month study, patients will undergo assessments including blood tests for cholesterol, triglycerides, glucose, inflammatory and oxidative stress markers, and hormones related to appetite. Questionnaires on sleepiness, quality of life, and physical activity will also be completed. CPAP compliance, adverse events, and cardiovascular events will be monitored to evaluate safety and treatment effects over the study period ending in January 2028.

Age: 35Years - 80YearsAll GendersPhase 4
1 location